Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2026
Event: Entry into a Material Definitive Agreement for a merger with Mentari Therapeutics, Inc.
Key Financial Metrics and Transaction Terms
This filing details a proposed merger rather than standard periodic financial results. Key transaction metrics include:
- Valuation Framework: Mentari Therapeutics, Inc. is valued at an equity value of $125,000,000 (or higher based on pre-closing financing).
- Pre-Closing Financing: A condition to closing is the receipt of not less than $150,000,000 by Mentari substantially concurrently with the merger closing.
- Pro Forma Ownership: Upon closing, pre-Merger Mentari stockholders will own approximately 98.49% of the combined company, while pre-Merger InMed shareholders will own approximately 1.51%.
- Consideration: Mentari shareholders will receive InMed Common Shares based on an Exchange Ratio. Series Seed Preferred Stock converts to Non-Voting Convertible Preferred Shares.
- Legacy Assets: Pre-Merger InMed shareholders will receive Contingent Value Rights (CVRs) for potential proceeds from the disposition of InMed's legacy assets.
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for either company.
Material Changes and Transaction Structure
The filing announces a fundamental change in control and corporate structure:
- Merger Mechanics: A two-step merger where Mentari merges into a wholly-owned subsidiary of InMed, followed by Mentari merging into a second subsidiary, resulting in Mentari becoming a wholly-owned subsidiary of InMed.
- Corporate Jurisdiction: InMed will continue from British Columbia, Canada, to Nevada.
- Corporate Name and Structure: The Company may change its name and effect a reverse stock split if mutually agreed upon.
- Board Composition: Directors and officers of the combined company will be designated by Mentari.
- Shareholder Approval: The transaction requires approval from InMed shareholders (due to issuance of >20% of outstanding shares and change of control) and Mentari stockholders.
Guidance, Risks, and Contingencies
Conditions to Closing:
- Shareholder approvals from both companies.
- Nasdaq listing approval for the combined company.
- Effectiveness of the Form S-4 registration statement.
- Receipt of required regulatory approvals.
- Completion of the $150,000,000 pre-closing financing.
Key Risks and Contingencies:
- Financing Failure: The merger is contingent on securing the $150 million pre-closing financing.
- CVR Uncertainty: There is no assurance that InMed legacy assets will generate proceeds; CVR holders may receive nothing.
- Termination: The agreement includes termination rights and fees if closing does not occur by the end date or if conditions are not met.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the transaction's completion, timing, and future operations, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the status of the $150,000,000 pre-closing financing commitment.
- Review the upcoming Form S-4 registration statement for detailed risk factors and proxy materials.
- Confirm the specific terms of the Exchange Ratio and beneficial ownership limitations.
- Assess the likelihood of Nasdaq listing approval and the potential impact of a reverse stock split.
- Understand the rights and potential payout scenarios associated with the Contingent Value Rights (CVRs).